Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis

Sponsor
AB Science
Study ID
NCT01450488
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to evaluate the activity of oral AB1010, administered at two dose levels during 3 years to patients with primary or secondary progressive multiple sclerosis.

Key Dates

Start date
Jun 30, 2005
Status verified
Dec 2018
Primary completion
Jul 31, 2007
Completion
Jan 31, 2010

Study Design

Enrollment
35 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: masitinib 3 mg/kg/day
  • Experimental: masitinib 6 mg/kg/day

Primary Outcome Measure

change in MSFC [ Time Frame: 12 months ]

Related Studies